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Abstract
Background: In a recent report of large-scale association analysis, a type 2 diabetes susceptibility locus near HNF1A
was identified in predominantly European descent populations. A population-specific G319S polymorphism in
HNF1A was previously identified in Aboriginal Canadians who have a high prevalence of type 2 diabetes. We aimed
to investigate the association of the HNF1A G319S polymorphism with incident type 2 diabetes and to assess
whether clinical risk variables for type 2 diabetes influence the association in an Aboriginal population.
Methods: Of 606 participants who were free of diabetes at baseline in 1993-1995, 540 (89.1%) participated in
10-year follow-up assessments in 2003-2005. Fasting glucose and a 75-g oral glucose tolerance test were obtained
to determine incident type 2 diabetes. Participants were genotyped for the HNF1A G319S polymorphism.
Interviewers administered questionnaires on smoking behavior.
Results: The incidence rates of type 2 diabetes were 14.2% (55/388) in major allele homozygotes and 31.2% (29/
93) in minor allele carriers (p < 0.001). The HNF1A G319S carrier status was associated with incident type 2 diabetes
(odds ratio [OR] 3.78 [95% CI 2.13-6.69]) after adjustment for age, sex, hypertension, triglyceride, HDL cholesterol,
and waist circumference. A statistical interaction was observed between HNF1A G319S and baseline active cigarette
smoking on the development of type 2 diabetes with similar adjustment (p = 0.006). When participants were
stratified by baseline smoking status, HNF1A G319S carriers who were active smokers had increased risk of
developing diabetes (OR 6.91 [95% CI 3.38-14.12]), while the association was attenuated to non-significance among
non-smokers (1.11 [0.40-3.08]).
Conclusions: The HNF1A G319S variant is associated with incident type 2 diabetes in Aboriginal Canadians.
Furthermore, cigarette smoking appears to amplify incident diabetes risk in carriers of HNF1A G319S.
Background
Type 2 diabetes has become a global epidemic, particu-
larly among Aboriginal Canadians who have a 3-5 times
higher prevalence of the disease compared to non-
Aboriginal Canadians [1]. Both environmental and
genetic factors have been attributed to this diabetes epi-
demic. Aboriginal populations have been exposed to a
rapid epidemiological transition in conjunction with
unique genetic susceptibility to diabetes [2]. We have
previously reported that a glycine to serine substitution
at codon 319 (G319S) of the HNF1A gene in an Abori-
ginal population was significantly associated with
increased type 2 diabetes prevalence in cross-sectional
analysis [3].
The HNF1A gene codes for a transcription factor,
hepatic nuclear factor (HNF)-1a, which plays an impor-
tant role in pancreatic b-cell function [4-6]. In various
populations, mutations in the HNF1A g e n ea r eac o m -
mon cause of the maturity-onset diabetes of the young
(MODY) [5-8], which is characterized by early age of
onset and a marked defect in insulin secretion. Unlike
these common HNF1A variants, the diabetes phenotype
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type 2 diabetes [3]. The S319 allele was associated with
accelerated onset of type 2 diabetes in a gene-dosage
manner [9], with ~7 years earlier onset for each copy of
the S319 allele carried.
In a recent report of large-scale association analysis, a
type 2 diabetes susceptibility locus near HNF1A was
identified in predominantly European descent popula-
tions [10]. However, there has been no prospective
study investigating whether the population-specific var-
iant, G319S, influences the development of type 2 dia-
betes in Aboriginal Canadians who have a high
prevalence of type 2 diabetes [11]. Accompanying this
high prevalence of type 2 diabetes, the population has
high prevalence rates of diabetes risk variables including
obesity and smoking [11-14], which are important public
health concern. However, no study has assessed whether
clinically measured risk variables influence the associa-
tion between the G319S variant and incident type 2 dia-
betes in Aboriginal Canadians. We aimed to determine
the association of the HNF1A G319S variant with the
incidence of type 2 diabetes and to assess whether clini-




The Sandy Lake Health and Diabetes Project is a
population-based cohort study designed to determine
the incidence of diabetes and its associated risk factors
in an Aboriginal Canadian population. Between 1993
and 1995, baseline data were obtained from 728 of
1018 (72%) eligible residents of Sandy Lake First
Nation aged 10-79 years [11]. Signed and informed
consent was obtained from all participants, and the
study was approved by the Sandy Lake First Nation
Band Council and University of Toronto Ethics Review
Committee.
Between 2003 and 2005, among 606 participants who
were free of diabetes at baseline, 540 (89.1%) partici-
pated in the 10-year follow-up evaluation [14]. Those
who did not return for follow-up (n = 66) were slightly
younger compared with respondents, but not different
according to sex and body mass index (BMI). After
excluding participants who died during follow-up, who
had missing baseline fasting and 2-hour postload glu-
cose, or who had diabetes at baseline defined by the
revised World Health Organization diagnostic criteria
[15], 492 men and women remained in the present
study.
Baseline data collection and laboratory procedures
At baseline, blood samples were collected after an 8- to
12-hour overnight fast to determine fasting glucose,
insulin, and lipid profile [11]. A 75-g OGTT was adminis-
tered, and a second blood sample for glucose was drawn
at 120 minutes postload. Glucose concentration was deter-
mined using the glucose oxidase method. Fasting plasma
insulin concentration was analyzed by radioimmunoassay
(Pharmacia, Piscataway, NJ). The homoeostasis model
assessment (HOMA) of insulin resistance was estimated
by the method of Matthews et al. [16]. Triglyceride, high-
density lipoprotein (HDL) and low-density lipoprotein
(LDL) cholesterol were determined using standard meth-
ods described in the Lipid Research Clinics manual of
operations [17].
Each anthropometric/blood pressure measurement
was performed twice, and the average was used in ana-
lyses. Height and weight were measured using an Accu-
stat wall-mounted stadiometer (Genentech Inc., San
Francisco, California) and a hospital balance beam scale
(Health-o-Meter Inc., Bridgeview, Illinois), respectively.
Waist circumference was measured at the iliac crest
using an inelastic tape.
Interviewer-administered questionnaires were used to
collect information on cigarette smoking behavior.
Active smokers were defined as those reporting current
use of cigarettes at the time of the baseline survey.
These participants were asked about their average num-
ber of cigarettes smoked daily. Smoking pack-years were
calculated by dividing the number of daily cigarettes
used by 20 and then multiplying by the smoking dura-
tion up to baseline data collection.
Genetic analyses
Restriction analysis with BseDI followed by polyacryla-
mide gel electrophoresis was used to detect the DNA
change underlying the HNF1A G319S amino acid var-
iant [3]. DNA sequence-proven controls were run as
standards for each genotyping reaction and a random
15% of samples were studied on another day with inde-
pendent genotyping reactions. The concordance
between replicates was 100%.
Definition of incident type 2 diabetes
Incident type 2 diabetes at follow-up was defined as the
presence of any one of the following at follow-up assess-
ments: 1) fasting plasma glucose ≥ 7.0 mmol/l or 2-hour
postload plasma glucose ≥ 11.1 mmol/l on a 2-hour
OGTT; 2) current use of insulin or oral hypoglycemic
agents; or 3) a positive response to the question: Have
you ever been diagnosed with diabetes by a nurse (prac-
titioner) or a doctor [14]? Of 492 participants, follow-up
blood samples were collected from 383 (77.8%) partici-
pants, while the diabetes status of 109 (22.2%) partici-
pants, who were not available for the follow-up blood
sampling visit, was ascertained based on self-reported
clinical diagnosis of diabetes through a phone interview.
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with and without blood samples at follow-up were not
statistically different (p = 0.85).
Statistical analysis
Distributions of continuous variables were assessed for
normality, and natural log transformations of skewed vari-
ables were used in statistical analyses. Descriptive statistics
for continuous variables were summarized as mean ± stan-
dard deviation or median (25
th-75
th percentile) for vari-
ables with a skewed distribution. Categorical variables
were summarized using proportions. Baseline characteris-
tics of S319 allele carriers and non-carriers were compared
using Welch’s modified t test or Chi-Square test as appro-
priate. Fisher’s exact test was used to assess HNF1A geno-
type frequencies. S/S319 and S/G319 genotypes were
combined in subsequent analyses due to a small number
of S/S319 carriers (n = 1) in the study population. For the
purpose of analysis and discussion, individuals with S/S
and S/G genotypes will be referred to as “S319 carriers”.
Multiple logistic regression analysis was conducted to
evaluate the association of the HNF1A G319S carrier
status with incident type 2 diabetes. The HNF1A G319S
polymorphism was assessed with adjustment for demo-
graphic information (age and sex) in model 1. Subse-
quent models were additionally adjusted for clinical risk
variables, including hypertension, dyslipidemia, hypergly-
cemia, and insulinemia, that were reported to be asso-
ciated with incident diabetes in this population [14]:
Model 2 was adjusted for model 1 variables in addition
to baseline hypertension, triglyceride, HDL cholesterol,
and waist circumference (or BMI); model 3 was adjusted
for model 2 variables in addition to baseline fasting glu-
cose; and model 4 was adjusted for model 3 variables in
addition to baseline HOMA-insulin resistance.
Interactions of HNF1A G319S with previously assessed
risk variables for incident diabetes [14], including age,
BMI, waist circumference, hypertension (yes/no), HDL
and LDL cholesterol, triglyceride, fasting insulin, pack-
year and active cigarette smoking (yes/no), were tested
by adding an interaction term to a model that included
the G319S carrier status and the main effect of interest
with adjustment for age, sex, hypertension, triglyceride,
and waist circumference. Data analyses were performed
with the use of SAS software, version 9.2 (SAS Institute,
Cary, NC), and with the consideration of two-sided p <
0.05 as statistically significant for all analyses.
Results
Baseline characteristics of S319 allele carriers and non-
carriers are presented in table 1. There were no statisti-
cally significant differences between carriers and non-
carriers in previously reported clinical risk factors for
incident type 2 diabetes and the cigarette smoking status
at baseline (p ≥ 0.05) (table 1). Of 481 participants who
were free of diabetes at baseline and genotyped for the
HNF1A G319S polymorphism, 388 (80.7%) G/G319, 92
(19.1%) S/G319, and 1 (0.2%) S/S319 carriers were
included in the study. The incidence of type 2 diabetes
was higher among S319 allele carriers compared to non-
carriers (table 2). The number of baseline active cigar-
ette smokers was not significantly different according to
the 10-year incident diabetes status at follow-up (p =
0.68): of 86 individuals with incident diabetes at follow-
up, 52 were active cigarette smokers at baseline (60.5%);
and of 404 diabetes-free individuals, 254 were active
cigarette smokers at baseline (62.9%).
Multiple regression models were constructed to assess
whether the HNF1A G319S polymorphism was asso-
ciated with incident type 2 (table 3). In the first model
adjusted for age and sex, the HNF1A G319S polymorph-
ism was associated with increased risk for developing
type 2 diabetes (odds ratio [OR] 3.24 [95% CI 1.90-
5.53]). When the models were further adjusted for clini-
cal risk factors for incident type 2 diabetes (models 2
and 3), the effect size increased (table 3). When model 2
included BMI adjustment instead of waist circumfer-
ence, the OR was similar to the model including waist
circumference (data not shown). In the model adjusted
for baseline age, sex, hypertension, triglyceride, waist cir-
cumference, HDL cholesterol, and fasting glucose, the
OR was 3.93 [95% CI 2.20-7.03]. The addition of
HOMA-insulin resistance to this model attenuated the
association slightly although it remained statistically sig-
nificant (3.83 [2.13-6.89]). The associations of HNF1A
G319S with longitudinal changes in glucose levels as
continuous variables were assessed. The HNF1A G319S
polymorphism was individually associated with 10-year
changes in fasting glucose (beta = 0.726, SE = 0.262, p =
0.006) and 2-hour postload glucose (beta = 0.932, SE =
0.469, p = 0.048) after adjusting for age and sex. With
adjustment for age, sex, hypertension, triglyceride, waist
circumference, and HDL cholesterol, the association of
the HNF1A polymorphism with 10-year changes in fast-
ing glucose remained significant (beta = 0.645, SE =
0.257, p = 0.01), while the association with 10-year
changes in 2-hour postload glucose was attenuated to
non-significance (beta = 0.880, SE = 0.470, p = 0.06).
There were no statistically significant interactions of
the HNF1A G319S polymorphism with previously
reported risk factors of incident diabetes in this popula-
tion [14] including age, BMI, waist circumference,
hypertension (yes/no), HDL and LDL cholesterol, trigly-
ceride, and fasting insulin on the outcome of incident
type 2 diabetes after adjustment for age, sex, hyperten-
sion, triglyceride, and waist circumference (all p ≥ 0.05)
(data not shown), except for fasting insulin (p = 0.03).
When participants were stratified by low and high
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tion of HNF1A G319S with incident type 2 diabetes
remained significant in both groups although the asso-
ciation in the low insulin group was stronger compared
to the high insulin group (OR 6.96 [95% CI 2.73-17.72]
and 2.53 [1.14-5.60], respectively).
An interaction was present between the HNF1A
G319S carrier status and active cigarette smoking at
baseline on the outcome of incident type 2 diabetes (p =
0.006), with adjustment for age, sex, hypertension, trigly-
ceride, and waist circumference. When participants were
stratified by active cigarette smoking status at baseline,
HNF1A G319S was strongly associated with incident
type 2 diabetes among active smokers (OR 6.91 [95% CI
3.38-14.12]), while the association was attenuated and
became non-significant among non-smokers (1.11 [0.40-
3.08]) (figure 1). Interactions of HNF1A G319S and
active cigarette smoking at baseline on longitudinal
changes in glucose levels as continuous variables were
assessed. An interaction between HNF1A G319S and
active cigarette smoking at baseline was not statistically
significant on the outcome of 10-year changes in fasting
glucose (p = 0.13) with adjustment for age, sex, hyper-
tension, triglyceride, and waist circumference. When
participants were stratified by baseline active cigarette
smoking status, however, HNF1A G319S was strongly
associated with fasting glucose changes among active
smokers (beta = 1.004, SE = 0.314, p = 0.0016), while
the association was not significant among non-smokers
(beta = 0.121, SE = 0.448, p = 0.79). An interaction
between HNF1A G319S and active cigarette smoking at
baseline was significant on the outcome of 10-year
changes in 2-hour postload glucose (p = 0.027) with
Table 1 Baseline characteristics of diabetes-free subjects according to the HNF1A G319S carrier status, the Sandy Lake
Health and Diabetes Project (1993-1995)
Characteristic G319/G319 S319/G319 + S319/S319 p-value
n (%) 388 (80.7) 93 (19.3)
Age (years)
a 26.9 ± 13.6 25.1 ± 10.8 0.18
Sex, male
b 156 (40.2) 47 (50.5) 0.07
Anthropometry
a
Body mass index (kg/m
2) 26.1 ± 5.85 25.9 ± 5.11 0.75
Waist circumference (cm) 96.3 ± 14.7 96.3 ± 12.5 0.95
Blood pressure
Systolic blood pressure (mmHg)
c 113.0 (104.0-120.0) 116.5 (106.5-121.0) 0.86
Diastolic blood pressure (mmHg)
a 65.1 ± 11.9 65.5 ± 11.8 0.77
Hypertension, yes
b,d 68 (17.3) 13 (14.0) 0.41
Lipid profile
HDL cholesterol (mmol/l)
a 1.25 ± 0.28 1.24 ± 0.27 0.77
LDL cholesterol (mmol/l)
a 2.49 ± 0.74 2.44 ± 0.78 0.56
Triglyceride (mmol/l)
c 1.16 (0.85-1.61) 1.78 (0.91-1.55) 0.78
Glucose homeostasis
Fasting glucose (mmol/l)
a 5.39 ± 0.49 5.33 ± 0.52 0.31
2-hour postload glucose (mmol/l)
a 5.63 ± 1.75 5.61 ± 1.88 0.93
Fasting insulin (pmol/l)
c 102.0 (71.0-145.0) 91.5 (57.0-132.0) 0.06
HOMA-Insulin resistance
c 3.38 (2.24-4.95) 2.85 (1.92-4.27) 0.05
Pack-year
c 1.25 (0.05-4.80) 1.73 (0.0-6.0) 0.83
Active cigarette smoker, yes
b 248 (64.3) 55 (59.1) 0.36
a. Mean ± standard deviation and Welch’s t test performed.
b. n (%) and Chi-Square test performed.
c. Medians (25
th-75
th percentile) and Welch’s t test performed on log transformation.
d. Hypertension is defined as a systolic blood pressure ≥ 130 mmHg or diastolic blood pressure of ≥ 85 mmHg or receiving antihypertensive medication therapy.
Abbreviation: HOMA, homoeostasis model assessment. n of subjects for each characteristic varying slightly due to occasional missing values.
Table 2 HNF1A genotype frequencies according to










No diabetes 333 (85.8) 64 (69.6) 0 (0) 64 (68.8)
Incident
diabetes
55 (14.2) 28 (30.4) 1 (100) 29 (31.2)
p < 0.001 < 0.001 (vs.
G319/G319)
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waist circumference. When participants were stratified
by baseline active cigarette smoking status, HNF1A
G319S was strongly associated with changes in 2-hour
postload glucose among active smokers (beta = 2.108,
SE = 0.611, p = 0.0007), while the association was not
significant among non-smokers (beta = -0.122, SE =
0.740, p = 0.87). An interaction between HNF1A G319S
and baseline pack-years was borderline significant (p =
0.05). Among those who provided both baseline and fol-
low-up smoking behavior information and who were
genotyped for HNF1A G319S, 142 of 420 (33.8%) parti-
cipants changed their smoking behavior during 10-year
follow-up (84 stopped smoking and 58 started smoking).
Therefore, we performed interaction testing between
changes in smoking behavior and the HNF1A G319S
polymorphism and determined that it was not statisti-
cally significant (p = 0.50). In addition, the S319 carrier
distributions among those who changed their smoking
behavior and those who did not were not significantly
different (p = 0.30).
Discussion
We found that the HNF1A G319S polymorphism was
associated with increased risk of developing type 2 dia-
betes after adjustment for previously reported baseline
clinical risk factors [14]. An interaction between the
G319S variant and active cigarette smoking at baseline
on the outcome of incident type 2 diabetes was evident
after adjustment for age, sex, hypertension, triglyceride,
and waist circumference. When participants were strati-
fied by active cigarette smoking status at baseline, S319
was strongly associated with increased risk of developing
type 2 diabetes among active smokers, while the associa-
tion was attenuated to non-significance among non-
smokers. Thus, HNF1A G319S is associated with the
future development of type 2 diabetes in this Aboriginal
population, and this association is amplified in the pre-
sence of cigarette smoking.
Recently, a type 2 diabetes susceptibility locus near
HNF1A was identified in large-scale association analysis
of predominantly European descent populations [10]. In
a prospective cohort study from Scandinavian countries,
a functional variant, HNF1A I27L, was associated with
increased future risk for type 2 diabetes in Scandinavian
countries (Hazard Ratio 1.2 [95% CI 1.1-1.3]) [18]. In
several studies investigated using case-control designs,
however, the positive association between genetic varia-
tions in HNF1A and type 2 diabetes was not observed
[19,20]. Holmkvist et al. [18] argued that case-control
studies are less effective at detecting small effects
because case and control subjects are often ascertained
differently. Hence, prospective cohort studies where all
individuals have undergone the same measurements to
identify the disease as in thep r e s e n ts t u d ya n dt h a to f
Holmkvist et al. [18] would circumvent this issue.
While the HNF1A G319S polymorphism demonstrated
reduced in vitro capacity to transactivate insulin
response, this disorder was not as severe as that seen in
some nonsense mutations in HNF1A that underlie
MODY type 3 [9]. Carriers of S319 do not develop
MODY; rather in the context of obesity and insulin
resistance, carriers appear to have a compromised ability
to mount an insulin response, resulting in earlier loss of
glycemic control [9]. Recently, the HNF1A G319S
Table 3 Multiple logistic regression analysis of the association of the G319S carrier status in HNF1A with the incidence
of type 2 diabetes
Covariate adjustment OR (95% CI) p
Model 1: age + sex 3.24 (1.90-5.53) < 0.0001
Model 2: model 1 + hypertension + triglyceride + HDL cholesterol + waist circumference 3.78 (2.13-6.69) < 0.0001
Model 3: model 2 + fasting glucose 3.93 (2.20-7.03) < 0.0001
Model 4: model 3 + HOMA-insulin resistance 3.83 (2.13-6.89) < 0.0001
Abbreviation: OR, odds ratio; CI, confidence interval; HOMA, homoeostasis model assessment. OR and 95% CI per 1-unit change (G319/G319, S319/G319 and
S319/S319 corded as 0, 1, and 1).
Figure 1 HNF1A G319S and incident type 2 diabetes stratified
by active cigarette smoking. Odds ratios are adjusted for age, sex,
hypertension, triglyceride, and waist circumference. The distributions
of S319 carriers within smokers and non-smokers were 55/303
(18.2%) and 38/176 (21.6%) and were not statistically different (p =
0.36).
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abnormal transcripts, with altered quantities of the nor-
mal splicing products and reduced total HNF1A tran-
script levels [21]. Thus, HNF1A G319S might
compromise insulin response through at least two
mechanisms: a failure of the mutant protein to transacti-
vate insulin response and decreased translation of nor-
mal HNF-1a due to abnormal splicing. Since HNF-1a
protein plays a key role in b-cell function [4], the reduc-
tion in normal HNF-1a activity may compromise b-cell
function and further explain the interaction between the
HNF1A G319S polymorphism and fasting insulin on the
outcome of incident type 2 diabetes observed in our
study.
The presence of cigarette smoking appears to amplify
the predisposition to the development of type 2 diabetes
in carriers of HNF1A G319S. To our knowledge, there is
no previously reported relation between smoking and loss
of glycemic control in individuals with other polymorph-
isms in HNF1A or in other MODY genes. A meta-analysis
report indicated that active smoking behavior might be
generally associated with increased risk for developing
type 2 diabetes [22]. In a European cohort study of partici-
pants aged 25-74 years, the risk for type 2 diabetes in men
increased in a dose-response manner with the increasing
number of cigarette consumption [23]. The underlying
mechanism whereby cigarette consumption increases dia-
betes risk is not entirely clear. Nonetheless, smoking has
been previously associated with insulin resistance [24,25].
In a non-randomized experimental trial, smoking acutely
impaired glucose tolerance and insulin sensitivity, and
increased serum LDL cholesterol, triglyceride, blood pres-
sure, and heart rate [24]. In a double-blind, cross-over,
placebo-controlled, randomized experimental study, nico-
tine infusion further aggravated the insulin resistance sta-
tus among individuals with type 2 diabetes, but not among
control subjects without diabetes [25]. Therefore, partici-
pants who were likely to have reduced insulin function
were more susceptible to the detrimental effects of nico-
tine. In addition, it was speculated by others that nicotine
or other agents in cigarette smoke might directly induce
pancreatic injuries [26] and effect insulin secretion by
inducing oxidative stress in the pancreas and subsequently
inducing loss of b-cells [27]. In the currently study popula-
t i o n ,w eh a v ep r e v i o u s l yr e p o r t e dt h a tb a s e l i n ea c t i v e
smoking status was not independently associated with
increase risk of incident type 2 diabetes [14]. However,
HNF1A G319S carriers who were active smokers had
increased risk of developing diabetes in the present study.
Hence, smokers who carry S319 allele, and therefore are
exposed to compromised insulin function [9], are at
increased risk of developing diabetes.
Limitations of our study include challenges of con-
ducting investigations in a remote community setting.
Specifically, we were unable to collect interim data to
analyze the time to the onset of type 2 diabetes. We
were also unable to obtain follow-up blood samples
from all participants: diabetes outcome assessments of
109 (22.2%) participants were by self-reported clinical
diagnosis only. This 22.2% without blood samples might
have caused under-reporting of incident diabetes. We
did not have a number of cigarettes smoked by former
smokers at baseline. Therefore, we excluded 75 former
smokers in our smoking dose-response analysis by pack-
years (15.6% of total participants who were genotyped).
This might have contributed to the attenuated interac-
tion observed between the G319S variant and smoking
dose in this study. We also note that our study results,
especially the smoking interaction, need to be confirmed
in other populations. Nonetheless, the current study was
able to retain a high 10-year follow-up rate of 89.1%
and was able to investigate the prospective association
between the population-specific genetic variation in
HNF1A and incident type 2 diabetes.
Conclusions
The population-specific HNF1A G319S variant was asso-
ciated with incident type 2 diabetes in Aboriginal Cana-
dians. Our results support that an environmental variable,
cigarette smoking, may influence the development of the
diabetes phenotype in the HNF1A G319S carriers. This is
a particularly important public health concern among
Aboriginal populations of Canada who have high preva-
lence rates of smoking and type 2 diabetes compared to
non-Aboriginal populations [1,28]. In future genetic stu-
dies, we recommend that potential gene-environment
interactions be taken into consideration when investigat-
ing the type 2 diabetes as an outcome.
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